GSK3359609 plus Tremelimumab for the Treatment of Advanced Solid Tumors

Trial Identifier: 207871
Sponsor: GlaxoSmithKline
Collaborator:
MedImmune
Start Date: November 2018
Primary Completion Date: June 2021
Study Completion Date: September 2021
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Australia, Victoria Melbourne, Victoria, Australia, 3000
Canada, Ontario Ottawa, Ontario, Canada, K1H 8L6
Canada, Ontario Toronto, Ontario, Canada, M5G 2M9
United States, Massachusetts Boston, Massachusetts, United States, 02215
United States, New York New York, United States, 10016-4744
United States, New York New York, United States, 10032
United States, Pennsylvania Pittsburgh, Pennsylvania, United States, 15232
United States, Texas San Antonio, Texas, United States, 78229